• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

June 18, 2021

Prostate Cancer Screening Recommended Earlier for Men With Family History of the Disease

Author(s):

Aislinn Antrim, Managing Editor

Researchers found that men with a family history of prostate cancer reached the screening risk threshold up to 12 years earlier than the general population.

A new study in Sweden has confirmed that men with a family history of prostate cancer have a greater risk of being diagnosed with advanced or fatal disease, suggesting that screening guidelines should be adjusted to include earlier screenings in this population.

Clinical guidelines for cancer screenings are intended to identify the disease early, according to the research, which was published in PLOS Medicine. Current guidelines note that men with a family history of prostate cancer have a greater risk and should begin screenings early, although the age at which these screenings should begin has remained unclear.

To define a recommended age, investigators conducted an analysis of all male residents of Sweden born after 1931, as well as their fathers. Between 1958 and 2015, they found that 88,999 out of 6,343,727 men were diagnosed with stage 3 or 4 prostate cancer or died from the disease.

The investigators then used these data to calculate the age at which men who had a father, brother, or son diagnosed with prostate cancer reached the “screening risk threshold,” meaning the same level of prostate cancer risk as those aged 50 years and older in the broader population. They chose this threshold because many guidelines recommend that screening begin at 50 years, according to the press release.

Men with a family history of prostate cancer reached the screening risk threshold up to 12 years earlier than the general population, the researchers said. However, they noted that men reached this threshold at different ages, depending on how many of their first-degree relatives had prostate cancer and at what age those relatives were diagnosed. Based on these findings, the investigators concluded that men with a family history of prostate cancer reach a high enough risk to begin screening anywhere from 2 to 11 years earlier than is currently recommended.

These findings could be used to provide greater personalization of screening guidelines, according to the press release. Further research could help validate these results in populations of different ethnicities, while also considering genetics and lifestyle differences.

“The one-size-fits-all policy in medicine belongs to the past. More and more risk-adapted approaches are needed instead to optimize use of restricted resources in health care,” said Elham Kharazmi, MD, PhD, co-leader of the study, in the press release.

REFERENCE

When should screening start for men with a family history of prostate cancer. News release. EurekAlert. June 1, 2021. Accessed June 8, 2021. https://www.eurekalert.org/pub_releases/2021-06/p-wss052721.php

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Image credit: Dr_Microbe | stock.adobe.com
Related Content
Advertisement
Doctor holding bladder model | Image Credit: © M+Isolation+Photo - stock.adobe.com
June 12th 2025

Mitomycin Intravesical Solution Receives FDA Approval for Non-Muscle Invasive Bladder Cancer

Alexandra Gerlach, Associate Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Oral herbal supplement -- Image credit: Vitalii Vodolazskyi | stock.adobe.com
June 12th 2025

You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment

Hanna Yakubi, PharmD Cody Angerman, PharmD Iris Zhao, PharmD, BCOP, BCPS, APh Saumya Papneja, PharmD, BCOP Christina Marengo, PharmD Mency Zhu, PharmD Ryan Beechinor, PharmD, BCPS, BCOP
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
FDA Approves Tablet Formulation of Zanubrutinib for All Indications
June 11th 2025

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

Luke Halpern, Assistant Editor
Image credit: David A Litman | stock.adobe.com
June 11th 2025

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Gillian McGovern, Associate Editor
Related Content
Advertisement
Doctor holding bladder model | Image Credit: © M+Isolation+Photo - stock.adobe.com
June 12th 2025

Mitomycin Intravesical Solution Receives FDA Approval for Non-Muscle Invasive Bladder Cancer

Alexandra Gerlach, Associate Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Oral herbal supplement -- Image credit: Vitalii Vodolazskyi | stock.adobe.com
June 12th 2025

You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment

Hanna Yakubi, PharmD Cody Angerman, PharmD Iris Zhao, PharmD, BCOP, BCPS, APh Saumya Papneja, PharmD, BCOP Christina Marengo, PharmD Mency Zhu, PharmD Ryan Beechinor, PharmD, BCPS, BCOP
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
FDA Approves Tablet Formulation of Zanubrutinib for All Indications
June 11th 2025

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

Luke Halpern, Assistant Editor
Image credit: David A Litman | stock.adobe.com
June 11th 2025

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Gillian McGovern, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.